<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 18 patients (30-56 years; median 49) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> underwent allogeneic HSCT from related (n=12) or unrelated (n=6) donors after a conditioning regimen comprising thiotepa, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, and TBI </plain></SENT>
<SENT sid="1" pm="."><plain>GVHD prophylaxis consisted of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (n=15) or tacrolimus (n=3) with short-course <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Four patients had low-risk disease (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> or complete remission after chemotherapy) and 14 patients had high-risk disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t, or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Grade II-IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD developed in six patients and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD in 10 </plain></SENT>
<SENT sid="4" pm="."><plain>With a median follow-up of 31 months, the 2-year survival probability is 75% for low-risk patients and 57% for high-risk patients </plain></SENT>
<SENT sid="5" pm="."><plain>One patient died of <z:hpo ids='HP_0001909'>leukemia</z:hpo> and six of treatment-related causes </plain></SENT>
<SENT sid="6" pm="."><plain>This conditioning regimen requires further study in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>